The Coagulation Factor Deficiency Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size for coagulation factor deficiency has been experiencing strong growth over the past years. It is expected to increase from $4.58 billion in 2024 to $4.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.0%.
The market for coagulation factor deficiency is anticipated to significantly increase in the upcoming years. Projections for 2029 estimate a market size of $6.64 billion, predicted to grow at a compound annual growth rat
Download Your Free Sample of the 2025 Coagulation Factor Deficiency Market Report and Uncover Key Trends Now!The key drivers in the coagulation factor deficiency market are:
• Growing adoption of gene therapies and personalized medicine
• Rising prevalence of coagulation disorders
• Expanding access to emerging markets and digital health solutions
• Continuous innovation in biomanufacturing technologies
The coagulation factor deficiency market covered in this report is segmented –
1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types
2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types
3) By End Users: Hospitals, Clinics, Home Care, Other End Users
Subsegments:
1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa, Other Recombinant Factors
2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII, Plasma-derived Factor IX, Plasma-derived Factor VII, Other Plasma-derived Factors
3) By Biologics: Monoclonal Antibodies, Gene Therapy Products
4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin
5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)
The key trends in the coagulation factor deficiency market are:
• The future of the market is being shaped by increasing adoption of gene therapies.
• Advances in gene editing technologies such as CRISPR and gene therapy delivery systems are emerging trends.
• The development of point-of-care diagnostic tools and wearables for coagulation monitoring are influencing the market.
• The trend towards plasma-free recombinant product development and biosimilar innovation is impacting the market future.
Major players in the coagulation factor deficiency market are:
• Pfizer Inc.
• F Hoffmann-La Roche Ltd.
• Bayer HealthCare Pharmaceuticals
• Sanofi Genzyme
• Novo Nordisk A/S
• Baxter International Inc.
• CSL Behring LLC
• Grifols S.A.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Swedish Orphan Biovitrum AB
• GC Biopharma Co. Ltd.
• Alnylam Pharmaceuticals Inc.
• Opko Health Inc.
• Kedrion Biopharma Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• LFB S.A.
• Biotest AG
• Spark Therapeutics Inc.
• Biogen Inc.
• Sangamo Therapeutics Inc.
• Centessa Pharmaceuticals Inc.
North America was the largest region in the coagulation factor deficiency market in 2024